Detección de lesiones preneoplásicas gástricas mediante niveles séricos de pepsinógeno en población chilena

F, José Ignacio Fernández; U, Xabier de Aretxabala; D, Ricardo Santander; T, Samuel Sabah; S, Jorge Maira; R, Alex Navarro; D, Marcela Planzer; L, Fernando Gómez; Etchart, Miguel; M, Iván Gallegos; Torrens, X. Martinez; P, Gerardo Fasce; Reydet, Ivette

doi:10.4067/s0034-98872007001200003

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zagari et al (264) analyzed 20 studies involving 4,241 participants and found that the sensitivity for diagnosing atrophic gastritis in the gastric body and antrum was 70.4% and 65.4%, respectively. However, few studies to date have measured the levels of pepsinogens for diagnosing gastric atrophy in Latin America (265) and Brazil (266) . Therefore, well-designed studies with a large sample size are necessary to define the performance of this panel in this region.…”

Section: Statement 19 Serological Analysis Of Gastric Atrophy Using Pmentioning

confidence: 99%

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Coelho

Marinho

Genta

et al. 2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the III Brazilian Consensus Conference on H. pylori infection held in 2012, in Bento Gonçalves, Brazil, and justify a fourth meeting to establish updated guidelines on the current management of H. pylori infection. Therefore, the Núcleo Brasileiro para Estudo do Helicobacter pylori e Microbiota (NBEHPM), association linked to Brazilian Federation of Gastroenterology (FBG) held its fourth meeting again in Bento Gonçalves, RS, Brazil, on August 25-27, 2017. Twenty-six delegates, including gastroenterologists, endoscopists, and pathologists from the five regions of Brazil as well as one international guest from the United States, participated in the meeting. The participants were invited based on their knowledge and contribution to the study of H. pylori infection. The meeting sought to review different aspects of treatment for infection; establish a correlation between infection, dyspepsia, intestinal microbiota changes, and other disorders with a special emphasis on gastric cancer; and reassess the epidemiological and diagnostic aspects of H. pylori infection. Participants were allocated into four groups as follows: 1) Epidemiology and Diagnosis, 2) Dyspepsia, intestinal microbiota and other afections, 3) Gastric Cancer, and, 4) Treatment. Before the consensus meeting, participants received a topic to be discussed and prepared a document containing a recent literature review and statements that should be discussed and eventually modified during the face-to-face meeting. All statements were evaluated in two rounds of voting. Initially, each participant discussed the document and statements with his group for possible modifications and voting. Subsequently, during a second voting in a plenary session in the presence of all participants, the statements were voted upon and eventually modified. The participants could vote using five alternatives: 1) strongly agree; 2) partially agree; 3) undecided; 4) disagree; and 5) strongly disagree. The adopted consensus index was that 80% of the participants responded that they strongly or partially agreed with each statement. The recommendations reported are intended to provide the most current and relevant evidences to management of H. pylori infection in adult population in Brazil.

show abstract

Section: Statement 19 Serological Analysis Of Gastric Atrophy Using Pmentioning

confidence: 99%

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Coelho

Marinho

Genta

et al. 2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…There are still few studies that relate levels of pepsinogens to the diagnosis of gastric atrophy in Latin America countries (31,32) . The aim of this study was to perform a prospective study to evaluate the concordance between OLGA and OLGIM systems, as well as GastroPanel ® performance in patients with premalignant lesions secondary to H. pylori chronic gastritis in Brazil.…”

Section: Introductionmentioning

confidence: 99%

Helicobacter Pylori Chronic Gastritis on Patients With Premalignant Conditions: Olga and Olgim Evaluation and Serum Biomarkers Performance

Coelho

Ribeiro

Gomes

et al. 2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: H. pylori chronic atrophic gastritis is a premalignant lesion, and its staging, according to OLGA and OLGIM systems aims to identify patients at increased risk of developing gastric cancer and optimize their follow-up. GastroPanel®, serum biomarkers panel including pepsinogen I (PGI), pepsinogen II (PGII), Gastrin 17 (G17) and anti- H. pylori antibodies is a noninvasive test for adenocarcinoma risk assessment in chronic H. pylori gastritis patients. OBJECTIVE: Prospective study to evaluate the concordance between OLGA and OLGIM grading systems, as well as to evaluate GastroPanel´s performance in patients with premalignant lesions secondary to H. pylori chronic gastritis in Brazil. METHODS: Patients with H. pylori chronic gastritis with premalignant lesions confirmed by histology were recruited from the gastrointestinal clinic of a University Hospital. All participants underwent endoscopic examination with biopsies which were reported according to updated Sydney system and premalignant lesions grading systems (OLGA and OLGIM). Blood samples were collected for biomarkers serological analysis (GastroPanel®, Biohit, Helsinki, Finland). The cut off values used to define high risk patients were those recommended by the manufacturer: PGI ≤30 µm/L and PGI/PGII ≤3. RESULTS: 41 patients were recruited: 28 women, 13 men, mean age 67.3 (47-89, SD: 9.6) years. By OLGA system, were obtained: OLGA 0 (n=1), OLGA I (n=7), OLGA II (n=17), OLGA III (n=9), and OLGA IV (n=7). By OLGIM system, were obtained: OLGIM 0 (n=14), OLGIM I (n=5), OLGIM II (n=10), OLGIM III (n=10), and OLGIM IV (n=2). Regarding histological staging among patients staged as low risk (OLGA/OLGIM 0, I and II) and high risk (OLGA/OLGIM III and IV) for gastric cancer development, the concordance rate found between both classifications was 85.4%. Considering high risk patients, those patients thus included in at least one of the systems the final distribution of our sample considered 24 low-risk and 17 high-risk patients for the development of gastric cancer. To determine by GastroPanel® whether the patient would be at low or high risk of developing gastric cancer, PGI showed a sensitivity, specificity and accuracy of 0.47 (95%CI: 0.26-0.69), 0.67 (95%CI: 0.47-0.82), and 0.58 (95%CI: 0.43-0.72), respectively, while PGI/PGII showed sensitivity, specificity and accuracy of 0.06 (95%CI: 0.01-0.27), 0.83 (95%CI: 0.64-0.93) and 0.51 (95%CI: 0.36-0.66), respectively. CONCLUSION: The histological classifications OLGA and OLGIM presented a substantial concordance rate among themselves. Simultaneous use of both histological classification systems increased the identification’s rate of high-risk patients. Biomarker analysis was not effective to distinguish low to high risk patients in the studied population. Further studies are needed to validate its use in clinical practice in Brazil.

show abstract